Overview

Candesartan Effect in Second Stage Arterial Hypertension

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Candesartan
Candesartan cilexetil
Hydrochlorothiazide